AstraZeneca PLC said Monday that a phase 3 trials of a three drug combination for the treatment of chronic obstructive pulmonary disease met eight out of its main objectives.
The Anglo Swedish pharmaceutical company said that the results of the Kronos trial, which compared a combination of budesonide glycopyrronium and formoterol with a number of rivals therapies, was published in the journal The Lancet Respiratory Medicine.
The three-drug cocktail called PT010 showed a significant reduction of exacerbations in patients with the disease compared with rival therapy, the company said.
AstraZeneca said it plans on making a first regulatory submission for the drug in the second half of the year.
No comments:
Post a Comment